A trial of a plant-based COVID-19 vaccine conducted by GSK and Medicago shows an overall 71% efficacy against disease caused by the predominant SARS-CoV-2 variants of concern observed during most of 2021, and 75% efficacy specifically against disease caused by Delta. The study excludes the Omicron variant, which was not in circulation at the time of the clinical trials.